Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
124.20    -5.80 (-4.46%)
Bid:
124.60
Ask:
125.00
Spread: 0.40 (0.321%)
Market Cap: £302.33m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

27 Nov 2024 17:30

RNS Number : 8988N
PureTech Health PLC
27 November 2024
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Citigroup Global Markets Limited

City of registered office (if applicable)

 

Country of registered office (if applicable)

GB

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

25-Nov-2024

6. Date on which Issuer notified

27-Nov-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

0.000000

0.000000

0.000000

0

Position of previous notification (if applicable)

5.053310

0.000000

5.053310

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

0

0.000000

Sub Total 8.A

0

0.000000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Citigroup Inc. (Chain 1)

Citigroup Inc. (Chain 1)

Citigroup Global Markets Holdings Inc.

Citigroup Inc. (Chain 1)

Citigroup Financial Products Inc.

Citigroup Inc. (Chain 1)

Citigroup Global Markets Holdings Bahamas Limited

Citigroup Inc. (Chain 1)

Citigroup Global Markets Limited

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

27-Nov-2024

13. Place Of Completion

Belfast

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBRBJTMTTTBBI
Date   Source Headline
29th May 20265:00 pmRNSHolding(s) in Company
27th May 20265:30 pmRNSHolding(s) in Company
22nd May 20265:00 pmRNSHolding(s) in Company
15th May 20267:00 amRNSCorrection - Holding(s) in Company
13th May 202612:00 pmRNS-RPRTC To Showcase Deupirfenidone at ATS Conference
8th May 20267:00 amRNSHolding(s) in Company
7th May 20266:27 pmRNSHolding(s) in Company
1st May 20267:00 amRNSPureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
29th Apr 20267:01 amRNSFinal Results
29th Apr 20267:00 amRNSPRTC Voluntarily Delists Nasdaq Depositary Shares
27th Apr 20266:09 pmRNSHolding(s) in Company
27th Apr 202612:05 pmRNS-RPRTC's Seaport Adds Neuropsychiatry Veteran to BOD
24th Apr 20265:58 pmRNSHolding(s) in Company
22nd Apr 202612:00 pmRNS-RPRTC's Gallop: Positive Ph1 Topline MDS & AML Data
16th Apr 20265:00 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSHolding(s) in Company
13th Apr 20267:05 amRNSNotice of Results
13th Apr 20267:00 amRNSPRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20266:00 pmRNS-RPRTC’s Seaport: GlyphAllo Paper Published
13th Mar 20264:35 pmRNSPDMR Notification RSU Vesting
2nd Mar 20267:00 amRNSTotal Voting Rights
25th Feb 20267:00 amRNS-RPRTC to Present at Leerink Healthcare Conference
19th Feb 20265:15 pmRNS-RPRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 202612:00 pmRNS-RPureTech to Present at the JP Morgan Conference
18th Dec 20257:00 amRNSPureTech Appoints Robert Lyne as CEO
10th Dec 20255:41 pmRNSResults of AGM on June 16, 2025 – Update Statement
10th Dec 20255:30 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RPRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
5th Dec 20256:00 pmRNS-RPRTC's Gallop: Positive Initial Topline AML Data
18th Nov 20255:30 pmRNSHolding(s) in Company
7th Nov 20256:18 pmRNSHolding(s) in Company
3rd Nov 20252:00 pmRNS-RPRTC: New LYT-200 AML Data + Update at ASH
22nd Oct 20257:00 amRNS-RPRTC: New IPF Data Show Benefit in Older Patients
17th Oct 20255:30 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSHolding(s) in Company
10th Oct 20255:59 pmRNSHolding(s) in Company
9th Oct 20256:10 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
29th Sep 20257:00 amRNS-RPRTC: New IPF Data Show Switch Patients Stabilized
24th Sep 20257:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Sep 20255:30 pmRNSHolding(s) in Company
19th Sep 20255:52 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNSHolding(s) in Company
11th Sep 202512:05 pmRNS-RPRTC's Seaport Advances 2nd Candidate Into Clinic
4th Sep 20255:30 pmRNSHolding(s) in Company
1st Sep 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report
21st Aug 202512:00 pmRNS-RPureTech Showcases Differentiated IPF Strategy
18th Aug 20257:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.